CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $575.1M, above the global median of $520.53M
- FinancialsAltman Z-Score 2.23: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.32%Above 5Y avg (1.96%)
Annual Rate
JPY 50.00Paid semi-annual
Payout Ratio
25.6%Sustainable
Next Ex-Dividend
Sep 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
90.54BJPY571.45M · vs all stocks (USD)
Trailing P/E
10.99xRevenue (TTM)
91.12BJPY575.10M · vs all stocks (USD)
Profit Margin
9.03%Beta
0.0630xvs all stocks
52-Week Change
4.22%vs all stocks
Forward Annual Dividend Yield
2.32%vs all stocks
Market Capitalization
90.54BJPY571.45M · vs all stocks (USD)
Enterprise Value
102.10BJPY644.39M · vs all stocks (USD)
Trailing P/E
10.99xForward P/E
10.10xPrice to Sales (TTM)
1.02xPrice to Book (MRQ)
0.8597xEnterprise to Revenue
1.12xEnterprise to EBITDA
5.08xProfit Margin
9.03%Operating Margin
9.10%Return on Assets (TTM)
4.91%Return on Equity (TTM)
8.44%Revenue (TTM)
91.12BJPY575.10M · vs all stocks (USD)
Revenue per Share (TTM)
2.07KJPYUpdated Aug 20, 2026Quarterly Revenue Growth
10.10%Gross Profit (TTM)
66.50BJPY419.75M · vs all stocks (USD)
EBITDA (TTM)
18.89BJPY119.24M · vs all stocks (USD)
Net Income (TTM)
8.23BJPY51.94M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-20.60%Operating Cash Flow (TTM)
9.96BJPY62.84M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
8.45BJPY53.36M · vs all stocks (USD)
Forward Annual Dividend Rate
50.00JPYUpdated Aug 20, 2026Forward Annual Dividend Yield
2.32%vs all stocks
Trailing Annual Dividend Rate
49.00JPYUpdated Aug 20, 2026Trailing Annual Dividend Yield
2.28%vs all stocks
5-Year Average Dividend Yield
1.96%vs all stocks
Payout Ratio
25.55%Minority Interest (Equity)
208.05MJPYFY2026 · Mar 31, 2026Revenue
89.16BJPYFY2026 · Mar 31, 2026Cost of Goods Sold
23.98BJPYFY2026 · Mar 31, 2026Gross Profit
65.18BJPYFY2026 · Mar 31, 2026Operating Income
12.37BJPY78.10M · vs all stocks (USD)
Pre-tax Income
11.20BJPYFY2026 · Mar 31, 2026Income Tax Expense
2.78BJPYFY2026 · Mar 31, 2026Net Income
8.42BJPYFY2026 · Mar 31, 2026EBIT
11.70BJPYFY2026 · Mar 31, 2026EBITDA (Income Statement)
18.89BJPYFY2026 · Mar 31, 2026Non-operating Interest Income
111.81MJPYFY2026 · Mar 31, 2026Non-operating Interest Expense
501.80MJPYFY2026 · Mar 31, 2026EPS (Basic)
191.80JPYFY2026 · Mar 31, 2026EPS (Diluted)
191.80JPYFY2026 · Mar 31, 2026Basic Shares Outstanding
44.08MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
44.08MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
37.40MJPYFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00JPYFY2026 · Mar 31, 2026Operating Cash Flow
4.40BJPYFY2026 · Mar 31, 2026Free Cash Flow
2.04BJPYFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
27.64BJPYFY2026 · Mar 31, 2026Starting Profit (CF Statement)
11.20BJPYFY2026 · Mar 31, 2026Other Non-cash Items
75.08MJPYFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.90BJPYFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-4.98BJPYFY2026 · Mar 31, 2026Capital Expenditures
-2.36BJPYFY2026 · Mar 31, 2026Net Intangibles (CF)
-534.75MJPYFY2026 · Mar 31, 2026Purchase of Investments
-125.00MJPYFY2026 · Mar 31, 2026Sale of Investments
299.00MJPYFY2026 · Mar 31, 2026Other Investing Activity
19.96MJPYFY2026 · Mar 31, 2026Net Investing Cash Flow
-2.17BJPYFY2026 · Mar 31, 2026Long-term Debt Issuance
1.15BJPYFY2026 · Mar 31, 2026Long-term Debt Payments
-4.53BJPYFY2026 · Mar 31, 2026Net Short-term Debt Issuance
7.49MJPYFY2026 · Mar 31, 2026Common Stock Repurchase
-258.00KJPYFY2026 · Mar 31, 2026Common Dividends Paid
-2.11BJPYFY2026 · Mar 31, 2026Net Financing Cash Flow
-5.49BJPYFY2026 · Mar 31, 2026Shares Outstanding
44.08MSharesUpdated Aug 20, 2026Float Shares
26.44MSharesUpdated Aug 20, 2026% Held by Insiders
29.71%vs all stocks
% Held by Institutions
19.05%vs all stocks
Total Cash (MRQ)
27.71BJPY174.87M · vs all stocks (USD)
Total Cash per Share (MRQ)
628.55JPYUpdated Aug 20, 2026Total Debt (MRQ)
36.47BJPY230.20M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3369xCurrent Ratio (MRQ)
1.55xBook Value per Share (MRQ)
2.45KJPYUpdated Aug 20, 2026Total Assets
179.70BJPY1.13B · vs all stocks (USD)
Total Current Assets
82.65BJPYFY2026 · Mar 31, 2026Total Liabilities
71.09BJPYFY2026 · Mar 31, 2026Total Non-current Assets
97.05BJPYFY2026 · Mar 31, 2026Total Non-current Liabilities
15.39BJPYFY2026 · Mar 31, 2026Total Current Liabilities
55.71BJPYFY2026 · Mar 31, 2026Cash & Cash Equivalents
27.76BJPYFY2026 · Mar 31, 2026Accounts Receivable
31.41BJPYFY2026 · Mar 31, 2026Inventory
20.90BJPYFY2026 · Mar 31, 2026Accounts Payable
4.90BJPYFY2026 · Mar 31, 2026Short-term Debt
33.83BJPYFY2026 · Mar 31, 2026Other Current Liabilities
10.37BJPYFY2026 · Mar 31, 2026Long-term Debt
5.27BJPYFY2026 · Mar 31, 2026Other Non-current Liabilities
1.27BJPYFY2026 · Mar 31, 2026Common Stock (Book)
6.59BJPYFY2026 · Mar 31, 2026Retained Earnings
73.55BJPYFY2026 · Mar 31, 2026Total Shareholders' Equity
108.60BJPY685.47M · vs all stocks (USD)
Treasury Stock
12.20BJPYFY2026 · Mar 31, 202652-Week Low
1.88KJPYUpdated Aug 20, 202652-Week High
2.43KJPYUpdated Aug 20, 202652-Week Change
4.22%vs all stocks
Beta
0.0630xvs all stocks
50-Day MA
2.08KJPYUpdated Aug 20, 2026200-Day MA
2.12KJPYUpdated Aug 20, 2026Avg 10-Day Volume
106.22KSharesUpdated Aug 20, 2026Avg 30-Day Volume
95.73KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
191.77JPYUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Cash Increase With FCF And Debt Decrease
Cash up four years running while long-term debt fell for three.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.23: grey zoneSignificant
Altman Z-Score: 2.23
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $575.1M, above the global median of $520.53MNotable
Revenue (USD): 575,100,382.534Global Median: 520,528,949.311
Levered free cash flow is $53.36M, above the global median of $16.24MNotable
Levered free cash flow (USD): 53,361,699.91Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ChemoCentryx Inc
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Yashima Denki Co., Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthMulti-Year Cash Increase With FCF And Debt Decrease
Dassault Systèmes SE
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthMulti-Year Cash Increase With FCF And Debt Decrease
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthMulti-Year Cash Increase With FCF And Debt Decrease